{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=19", "query": { "intervention": "Control Vaccine 3", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 539, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+3&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T03:58:13.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04350138", "title": "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gonococcal Infection" ], "interventions": [ { "name": "Meningococcal Group B Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 2606, "start_date": "2020-12-29", "completion_date": "2026-07-08", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04350138" }, { "nct_id": "NCT04886596", "title": "Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "RSVPreF3 OA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 26675, "start_date": "2021-05-25", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886596" }, { "nct_id": "NCT07806617", "title": "Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Warts", "Verruca (Warts)", "Verruca Vulgaris" ], "interventions": [ { "name": "9-valent human papillomavirus vaccine", "type": "BIOLOGICAL" }, { "name": "Sterile Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-09-02", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07806617" }, { "nct_id": "NCT05294588", "title": "Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gonorrhea Male" ], "interventions": [ { "name": "Cefixime", "type": "DRUG" }, { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Neisseria gonorrhoeae strain FA1090", "type": "BIOLOGICAL" }, { "name": "Meningococcal Group B Vaccine", "type": "BIOLOGICAL" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus-diptheria Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 65, "start_date": "2022-04-18", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05294588" }, { "nct_id": "NCT00516659", "title": "ETEC Logistics Trial (TREK)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diarrhea" ], "interventions": [ { "name": "Heat-Labile Enterotoxin of Escherichia coli (LT)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Intercell USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 201, "start_date": "2006-05", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-03-14", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 13, "location_summary": "Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516659" }, { "nct_id": "NCT05992935", "title": "Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Norovirus Acute Gastroenteritis" ], "interventions": [ { "name": "mRNA-1403", "type": "BIOLOGICAL" }, { "name": "mRNA-1405", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1407, "start_date": "2023-08-25", "completion_date": "2026-09-22", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 14, "location_summary": "Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Meridian", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05992935" }, { "nct_id": "NCT07132125", "title": "Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HPV Vaccination Intent" ], "interventions": [ { "name": "Default-style LLM chatbot", "type": "BEHAVIORAL" }, { "name": "Conversational-style LLM chatbot", "type": "BEHAVIORAL" }, { "name": "Public health informational materials", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 930, "start_date": "2025-03-17", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07132125" }, { "nct_id": "NCT00345670", "title": "Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MEDI-534", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "9 Years", "sex": "ALL", "summary": "1 Year to 9 Years" }, "enrollment_count": 120, "start_date": "2006-06", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2008-09-03", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 12, "location_summary": "Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Shawnee", "state": "Kansas" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Bardstown", "state": "Kentucky" }, { "city": "Crestview Hills", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345670" }, { "nct_id": "NCT04611802", "title": "A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV Infection", "Covid19" ], "interventions": [ { "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)", "type": "BIOLOGICAL" }, { "name": "Placebo (Initial Vaccination Period)", "type": "OTHER" }, { "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)", "type": "BIOLOGICAL" }, { "name": "Placebo (Crossover Vaccination period)", "type": "OTHER" }, { "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 33000, "start_date": "2020-12-27", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 144, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04611802" }, { "nct_id": "NCT06838000", "title": "Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "PCV21", "type": "BIOLOGICAL" }, { "name": "20vPCV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Months to 17 Years" }, "enrollment_count": 1268, "start_date": "2025-02-28", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-19T03:58:13.222Z", "location_count": 17, "location_summary": "Paramount, California • Doral, Florida • Hialeah, Florida + 13 more", "locations": [ { "city": "Paramount", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06838000" } ] }